Semaglutide Fails to Slow Alzheimer's Progression
The disappointing findings from a study on semaglutide are scheduled to be presented at an upcoming Alzheimer's disease conference. The results have not yet been published in a peer-reviewed journal.
According to Martin Holst Lange, chief scientific officer at Novo Nordisk, the company felt obligated to explore semaglutide's potential due to the significant unmet need in Alzheimer's disease, despite recognizing a low probability of success.
Lange stated that while semaglutide was not effective in slowing Alzheimer's disease progression, it continues to offer significant benefits for individuals with type 2 diabetes, obesity, and related conditions.
Patients participating in the Evoke trials were between 55 and 85 years old and exhibited mild cognitive impairment or mild dementia resulting from Alzheimer's disease.
Dementia progression was carefully monitored using tests and interviews throughout the study.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Treatment using semaglutide led to improvements in Alzheimer's disease-related biomarkers. However, this did not translate into a delay in the progression of the disease itself.
Need for Multifaceted Approaches
According to Fiona Carragher, chief policy and research officer at Alzheimer's Society, it was "very disappointing" these eagerly awaited results were not what everyone had hoped for, "no trial is wasted".
Carragher mentioned that there are currently over 130 Alzheimer's drugs undergoing clinical trials, with approximately 30 in late-stage trials, which represents the final step before regulatory consideration.
Dr. Kohlhaas stated that these trial results emphasize that Alzheimer's is influenced by various biological processes and that a singular approach is unlikely to be sufficient. Health tracking apps like Shotlee can help monitor overall well-being, but Alzheimer's requires targeted interventions.
She added, the field now needs to focus on gaining a more comprehensive understanding of these processes and developing treatments that can be used in combination to address the disease from multiple angles.
